

Toluene disruption of the functions of L1 cell adhesion molecule at concentrations associated with occupational exposures

Kimberly M.R. White¹, Julia A. Sabatino¹, Min He¹, Natalie Davis¹, Ningfeng Tang¹ and Cynthia F. Bearer¹

BACKGROUND: Prenatal toluene exposure can cause neurodevelopmental disabilities similar to fetal alcohol syndrome. Both share neuroanatomic pathologies similar to children with mutations in L1 cell adhesion molecule (L1). L1 mediates neurite outgrowth (NOG) via signaling through ERK1/2, which require trafficking of L1 through lipid rafts. Our objective is to determine if toluene inhibits L1-mediated NOG and toluene inhibits L1 signaling at concentrations achieved during occupational exposure.

METHODS: Concentrations of toluene reflective of blood concentrations achieved in solvent abusers and occupational settings are used. Cerebellar granule neurons (CGN) harvested from postnatal day 6 rat pups are plated on coverslips coated with poly-L-lysine (PLL) alone or PLL followed by laminin. L1 is added to the media of CGN plated on PLL alone. Toluene is added 2 h after plating. Cells are fixed at 24 h and neurite length is measured. ERK1/2 activation by L1 in CGN is analyzed by immunoblot.

RESULTS: Toluene significantly reduced mean neurite length of CGN exposed to L1 but not laminin. Toluene significantly reduced L1-mediated ERK1/2 phosphorylation.

CONCLUSION: Results suggest that toluene inhibits L1-lipid raft interactions at occupationally relevant concentrations and may lead to a fetal solvent spectrum disorder similar to fetal alcohol spectrum disorder.

Toluene is a ubiquitous, volatile organic solvent. Its presence is widespread in the home and in industrial and outdoor environments. Toluene is found in household products (e.g., nail polish, paints, glues, and cleaners), is a component of octane-boosting gasoline, and is used industrially for its powerful dissolving properties (1,2). Expectant mothers and children can be exposed to toluene inadvertently via the mentioned environmental/occupational exposures and/or intentionally through inhalant abuse (3).

Birth outcome studies (4–9) and animal models (6,10,11) have shown that prenatal toluene exposure is detrimental to neurodevelopment in fetuses and neonates. Children born to mothers with known prenatal toluene abuse can develop fetal solvent syndrome, showing traits similar to those born with

fetal alcohol syndrome (i.e., growth delays, impaired neurobehavioral development, and facial dysmorphism (12–16)). Both fetal alcohol syndrome and fetal solvent syndrome have neuroanatomic pathologies similar to children with mutations in the L1 cell adhesion molecule (L1) (14,17–23). Thus, L1 has been implicated in the pathogenesis of prenatal ethanol and toluene teratogenicity. L1 has four cytoplasmic tyrosines whose phosphorylation status mediates L1 function, including aiding in axon fasciculation, the trafficking of neuronal precursors, cell-cell adhesion, and neurite outgrowth (NOG) (24).

Ethanol has been shown to disrupt NOG of cerebellar granule neurons (CGN) derived from postnatal day 6 rat pups (equivalent to third trimester human fetal cerebellum (25)) plated on L1 but not on laminin (26,27). Laminin binds to the integrin receptor to promote NOG and is not dependent on lipid rafts, whereas L1-mediated NOG is dependent on lipid rafts (28,29). This suggests that ethanol inhibits NOG through an effect on lipid rafts. Lipid rafts are specialized, dynamic microdomains of the plasma membrane (30). We have previously shown that ethanol increases the proportion of L1 in lipid rafts and inhibits L1 activation of a cascade of downstream events that normally initiates NOG (29,31–33). These downstream events include activation of pp60src and ERK1/2, phosphorylation of L1 tyrosines, and the dephosphorylation of tyrosine 1176 in the cytoplasmic domain of L1 (32–34). Pp60src is particularly interesting as it is a lipid raft-associated protein (35).

The goals of the current study are to determine (i) at what concentrations does toluene, like ethanol, inhibit L1-mediated NOG and (ii) if toluene inhibits L1 signaling. We investigate the effect of toluene (0.02–2.0 mmol/l) on L1- and laminin-mediated NOG of CGN harvested from postnatal day 6 rat pups. The selected range of toluene concentrations is representative of blood toluene concentrations achieved by solvent abusers and occupationally exposed workers (Table 1). Furthermore, we evaluate the effect of 0.1 mmol/l toluene on the activation of ERK1/2 by L1.

RESULTS

Neurite length of CGN plated on a substrate of poly L-lysine (PLL), L1 alone, L1 with toluene (0.02–2.0 mmol/l), and L1

¹Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland. Correspondence: Cynthia F. Bearer (cbearer@pediatrics.umaryland.edu)

Received 5 July 2015; accepted 5 January 2016; advance online publication 30 March 2016. doi:10.1038/pr.2016.40

Table 1. Blood toluene concentrations from various modes of exposure

Ref.	Exposure	N	Toluene, µg/l (mmol/l) median	Toluene, µg/l (mmol/l); maximum value reported	Metric of maximum value reported
(40)	General population (NHANES: females, 2003–2004)	689	0.085 (0.92 × 10 ⁻⁶)	0.58 (6.92 × 10 ⁻⁶)	95 th%
(40)	General population (NHANES: females, 2005–2006)	1,609	0.110 (1.01 × 10 ⁻⁶)	0.69 (6.35 × 10 ⁻⁶)	95 th%
(40)	General population (NHANES: females, 2001–2002)	504	0.15 (1.63 × 10 ⁻⁶)	0.81 (8.79 × 10 ⁻⁶)	95 th%
(41)	General population (NHANES III, 1988–1994)	604	0.28 (3.04 × 10 ⁻⁶)	1.5 (1.6 × 10 ⁻⁵)	95 th%
(42)	Lower Rio Grande Valley Residents	18	0.17 (1.8 × 10 ⁻⁶)	0.7 (7.6 × 10 ⁻⁶)	Maximum
(43)	Office work, nonsmoker, no ETS ^a	42	0.274 (2.97 × 10 ⁻⁶)	0.578 (6.27 × 10 ⁻⁶)	90 th%
(43)	Office work, nonsmoker, ETS ^a	27	0.348 (3.78 × 10 ⁻⁶)	0.891 (9.67 × 10 ⁻⁶)	90 th%
(43)	Office work, smoker	31	0.547 (5.94 × 10 ⁻⁶)	1.225 (1.33 × 10 ⁻⁵)	90 th%
(44)	Woodworking, nonsmoker	15	0.428 (4.65 × 10 ⁻⁶)	6.04 (6.56 × 10 ⁻⁵)	Maximum
(44)	Woodworking, smoker	10	0.78 (8.47 × 10 ⁻⁶)	5.148 (5.59 × 10 ⁻⁵)	Maximum
(45)	General public (Rome)	269	0.500 (5.43 × 10 ⁻⁶)	7.1 (7.7 × 10 ⁻⁵)	98 th%
(46)	Street vending (end of shift)	6	0.51 (5.53 × 10 ⁻⁶)	4.6 (5.0 × 10 ⁻⁵)	Maximum
(41)	Office workers	12	0.53 (4.88 × 10 ⁻⁶)	1.2 (1.11 × 10 ⁻⁶)	95 th%
(46)	Office work (end of shift)	8	0.61 (6.62 × 10 ⁻⁶)	7.4 (8.0 × 10 ⁻⁵)	Maximum
(46)	Service station attendants (end of shift)	25	1.2 (1.3 × 10 ⁻⁵)	4.7 (5.1 × 10 ⁻⁵)	Maximum
(47)	Print work (end of shift)	771	266.3 (0.003)	2,529 (0.027)	Maximum
(45)	Print work (plastification) (end of shift)	14	1.181 (0.013)	2,120 (0.023)	Maximum
(48)	Print work (rotogravure) (end of shift)	20	1.470 ^b (0.016)	5,910 (0.064)	Maximum
(49)	Solvent abuse (prisoners)	6	25,400 (0.276)	31,400 (0.341)	Maximum
(50)	Solvent abuse (homeless adolescents in Brazil)	57	16,600 (0.181)	83,700 (0.908)	Maximum

^aEnvironmental tobacco use. ^bAverage.




Figure 1. Neurite length distribution. Neurite lengths are shown of a single preparation of rat postnatal day 6 cerebellar granule neurons plated on poly-L-lysine (PLL) and treated with or without L1-Fc (L1) and/or different concentrations of toluene (this preparation did not include an L1 + 2.0 mmol/l toluene condition). Each measured neurite is plotted as its length vs. the percent of neurites longer than that particular length. +, no additions; Δ, L1 only; □, L1 + 0.02 mmol/l toluene; ■, L1 + 0.05 mmol/l toluene; ▲, L1 + 0.1 mmol/l toluene; x, L1 + 1.0 mmol/l toluene; ●, L1 + 25 mmol/l ethanol.

with ethanol (25 mmol/l) (used as a positive control) was determined. PLL is a synthetic cell adhesive polymer which is permissive for neurite outgrowth (36). The neurite length promoting effect of L1 and laminin can be determined by

comparing the neurite lengths of CGN grown on PLL to that of CGN grown on PLL either coated with laminin, or treated with L1. Shown in **Figure 1** are the neurite lengths of one representative experiment using one cell preparation and, for this experiment, toluene concentrations of 0.02–1.0 mmol/l. Neurite lengths were plotted as the percent of neurites longer than each neurite so that each curve can be compared although the numbers of neurites per condition varied. As can be seen, increasing concentrations of toluene reduced the lengths of the longest neurites without shifting the lengths of the shortest neurites. To summarize the effect of toluene on neurite length, the mean neurite length from each condition for each cell preparation was calculated, then the mean of the mean neurite length from each experiment was determined as shown in **Figure 2**. As previously shown, L1 significantly increased the mean neurite length over PLL alone (26,29,37). Ethanol significantly decreased the mean neurite length of CGN treated with L1. Toluene at all tested concentrations significantly decreased mean neurite length of CGN treated with L1.

To determine if the decrease of neurite length by toluene was specific to L1 or was a general effect on neurite length, we plated CGN on laminin alone, laminin with toluene (0.02–2.0 mmol/l), and laminin with ethanol (25 mmol/l). As previously shown, laminin significantly increased neurite length over PLL alone (26). Ethanol and toluene at all tested concentrations did not have a significant effect on the length of neurites of CGN grown on laminin (**Figure 3**).

Next, we tested the capability of toluene to inhibit L1 activation of ERK1/2. Because ERK1/2 is activated through its




Figure 2. Mean neurite length of cerebellar granule neurons treated with L1. Rat postnatal day 6 cerebellar cells were isolated and plated on poly-L-lysine (PLL). L1 was added to some cultures following plating. Cells plated on PLL were not treated further. Cells plated on PLL and treated with L1, following a 2-h incubation, were treated with one of the following conditions: 25 mmol/l ethanol (EtOH) or 0, 0.05, 0.02, 0.1, 0.2, 0.5, 1, or 2 mmol/l toluene. Cells were incubated for an additional 24 h and then fixed, and neurite length was measured. The error bars indicate \pm SEM. Plating cells on L1 significantly increased mean neurite length over cells plated on PLL alone, and toluene at all concentrations significantly reduced mean neurite length (PLL vs. L1, $*P < 10^{-8}$, L1 vs. L1 + toluene or ethanol, $**P < 0.0005$, $^{\ddagger}P = 0.02$, $^{\ddagger}P < 0.05$, two-tailed paired *t*-test).

phosphorylation, we measured the relative densitometric units of phosphoERK1/2 normalized to total ERK1/2 after exposing CGN to toluene. We used a concentration of 0.1 mmol/l toluene as it was within the range of blood concentrations which have been measured (Table 1). As previously shown, phosphoERK1/2 was significantly increased following addition of a cross-linked monoclonal antibody (cASCS4, which activates L1) over PLL alone (33). However, the cASCS4-induced increase in phosphoERK1/2 was significantly less in the presence of 0.1 mmol/l toluene at 10 min (Figure 4).

DISCUSSION

The goals of the current study were to determine if toluene, like ethanol, inhibits L1-mediated NOG. Our results suggest that toluene inhibits L1-mediated NOG, which may be caused via effects of toluene on lipid rafts. The present study is the first report of toluene-induced inhibition of L1-mediated NOG in CGN, as initially shown for ethanol (26,27). Toluene significantly reduced neurite length of CGN plated on L1 (Figures 1 and 2). However, toluene did not reduce neurite length of CGN plated on laminin (Figure 3). Because L1-mediated NOG is dependent on lipid rafts whereas laminin is not (28), our results suggest that toluene disrupts L1-lipid raft interactions.

Normal L1-lipid raft interactions that lead to L1-mediated NOG involve a cascade of downstream events, including L1-mediated activation of both pp60src and ERK1/2, phosphorylation of L1 tyrosines, and the dephosphorylation of tyrosine 1176 of L1, all of these actions of L1 are inhibited by ethanol (32,33). In the present study, our results suggest that




Figure 3. Mean neurite length of cerebellar granule neurons plated on laminin. Rat postnatal day 6 cerebellar granule cells were isolated and plated on poly-L-lysine (PLL) or laminin. Cells plated on PLL were not treated further. Cells plated on laminin, following a 2-h incubation, were treated with one of the following conditions: 25 mmol/l EtOH or 0, 0.05, 0.1, 0.2, 0.5, 1, or 2 mmol/l toluene. Cells were incubated for additional 24 h and then fixed, and neurite length was measured. Plating cells on laminin significantly increased mean neurite length over cells plated on PLL alone ($*P < 0.02$, paired *t*-test). Ethanol or toluene at any dose did not significantly reduce mean neurite length of CGN plated on laminin ($P > 0.2$, two-tailed paired *t*-test). The error bars indicate \pm SEM.

toluene disturbs this cascade at least at the level of ERK1/2 activation by inhibiting the L1-mediated phosphorylation of ERK1/2. PhosphoERK1/2 was significantly reduced in the presence of 0.1 mmol/l toluene.

Identifying toluene as well as ethanol as disruptors of L1-lipid raft interactions suggests a common neurotoxic mechanism of fetal alcohol syndrome and fetal solvent syndrome. In a review of literature reporting toluene concentrations in different populations, it was found that toluene blood concentrations differ by orders of magnitude between the general population (median values from 0.085 to 0.50 μ g/l), occupationally exposed workers (median values of 1.2–1470 μ g/l in occupations with increasing exposure) and two different groups of inhalant abusers (median values of 16,600–25,400 μ g/l) (Table 1). Differences in the median values of these populations can be due to the number of subjects in each study, the differing levels of exposure even within each group, and the time of blood sampling relative to the time of exposure. Toluene concentrations used in this study were reflective of blood toluene concentrations easily achieved by solvent abusers and in highly exposed workers in certain occupational settings (i.e., print work) (Table 1). Toluene significantly reduced NOG of CGN at all tested concentrations and significantly reduced L1 activation of ERK1/2 in CGN at 0.1 mmol/l toluene, suggesting that toluene is toxic to CGN not only at high blood toluene concentrations achieved by solvent abusers but also at an order of magnitude lower concentrations that are achieved in occupational settings. The low concentrations at which toluene can reduce NOG and inactivate ERK1/2 implies




Figure 4. Toluene inhibits L1-mediated ERK1/2 activation. (a) Representative images of ERK1/2 and phosphoERK1/2 immunoblots. (b) Densitometric quantification of ERK1/2 phosphorylation corrected for total ERK1/2, plotted as relative densitometric units relative to the MslgG control. The bars indicate the mean ± SEM. The single asterisk (*) indicates a statistically significant increase in ERK1/2 activation in the presence of cIASCS4 vs. MslgG control alone (**P* < 0.002, two-tailed paired *t*-test). The double asterisk (**) indicates a statistically significant decrease in phosphorylated ERK1/2 following toluene treatment of 0.1 mmol/l (***P* < 0.01, two-tailed paired *t*-test).

that fetal solvent syndrome is not a diagnosis reserved for children born only to heavy solvent abusing women, but is indeed a spectrum disorder, similar to fetal alcohol spectrum disorder.

Conclusions

Our work suggests that toluene, similar to ethanol, disrupts L1-lipid raft interactions at blood toluene concentrations achieved not only in substance abusers but also in individuals in occupational settings.

METHODS

Antibodies

Antibodies used in the NOG assay were mouse monoclonal anti-β III tubulin obtained from Sigma (St. Louis, MO) and goat anti-mouse IgG (heavy and light chain) conjugated to Alexa 488 which is obtained from Invitrogen (Grand Island, NY). Antibodies used in the ERK1/2 activation and immunoblot assays were the following: rabbit polyclonal antibody against dually phosphorylated, activated ERK1/2 (New England Biolabs, Ipswich, MA), rabbit polyclonal antibodies against ERK1/2 (anti-ERK1/2), goat polyclonal antibodies to rabbit IgG (H+L) conjugated to hydrogen peroxidase (Jackson

Immuno-Research, West Grove, PA), and goat anti-mouse IgG conjugated to Oregon Green (Molecular Probes, Eugene, OR).

Mouse monoclonal antibodies to rat L1 (ASCS4) were produced from a hybridoma cell line developed by P. H. Patterson and obtained from the Developmental Studies Hybridoma Bank (The University of Iowa) as previously described (33). L1-Fc, a chimeric protein consisting of the extracellular domain of L1 and Fc domain of IgG, was obtained from R&D Systems in Minneapolis, MN.

Cell Cultures

CGN from 6-d-old Sprague-Dawley rat pups were prepared as previously described (26,29) and approved by the University of Maryland School of Medicine Institutional Animal Care and Use Committee. This is an animal only study; therefore, institutional review board approval was not necessary. Viability of CGN was assessed with trypan blue and is routinely >90%. These cells have been characterized as >90% CGN (28,38,39).

Preparation of Coverslips

Cover slips obtained from Fisher Scientific (Hanover Park, IL) were cleaned and placed in the bottom of each of a 24-well Costar tissue culture flat bottom plate. PLL-coated plates were prepared as follows: One milliliter ice-cold 0.1% PLL was placed into each of the 24 wells. The wells were sealed and placed in the refrigerator at 4 °C overnight. Laminin-containing wells were prepared as follows: PLL-containing wells were washed in ice-cold phosphate-buffered saline (PBS) three times, then 1 ml of a 2 mg/ml laminin solution in PBS was added to each well. The plate was sealed and placed in the refrigerator overnight at 4 °C. L1-containing wells were prepared as follows: just prior to the addition of CGN, each PLL-containing well was washed in ice-cold PBS three times. CGN in tissue culture media were added to the well in a final volume of 1 ml. L1-Fc was added following CGN to give a final concentration of 0.2 μg/ml.

Neurite Outgrowth Assay

CGN were prepared in Neurobasal media (Gibco, Rockville, MD) with the following additions: 2% B27 supplement (Gibco), 20 mmol/l L-glutamine, 6 g/l glucose, 20 mmol/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.2, penicillin/streptomycin, and added to the tissue culture wells containing the prepared coverslips. CGN cultures were incubated for 2h at 37 °C in 5% CO₂ to allow for cell adhesion. Two hours after plating, plates were treated with toluene dissolved in medium. First, a 2 mmol/l toluene stock solution was made, from which a serial dilution was performed to attain smaller concentrations of toluene, and added to cell cultures. Two plates of CGN were kept as untreated controls with PLL alone, two plates of CGN were treated only with laminin, and two plates were treated only with L1-Fc. Cells were grown for 24h in a humid atmosphere of 90% air, 5% CO₂ at 37 °C. After 24h, the media was removed, and cells were washed with ice-cold PBS three times. The cells were then fixed in 4% paraformaldehyde for 30 min at room temperature, followed by three more washes of PBS. Blocking solution (3% bovine serum albumin (BSA)/0.2% Triton X-100/PBS) was added to each coverslip for 1 h at 37 °C, or overnight at 4 °C. Blocked cells were exposed to mouse monoclonal anti-tubulin β-III for 1 h at 37 °C and washed three times with PBS followed by Alexa 488 anti-mouse IgG for 1 h at 37 °C, washed three times with PBS, and mounted on glass slides. Eligible neurites were identified by a masked investigator in an *a priori* design. The eligible neurons were visualized using a Zeiss Observer Z1 fluorescence inverted microscope, and images were captured using Axiovision camera software (Carl Zeiss Oberkochen, Germany). Neurite length was measured using Image J software (National Institutes of Health, Bethesda, MD). Only neurons containing neurites that meet the following criteria were measured: (i) The neurite is as long as the width of the soma, (ii) The neurite is not in contact with another neuron, (iii) The neuron must be single and not in a cluster. At least 30 neurites from each coverslip were measured.

ERK1/2 Assay

CGN (6 × 10⁵ cells) were plated on PLL-coated 60-mm tissue culture dishes in Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum and 20 mmol/l HEPES, pH 7.2, and grown overnight. One hour prior to the addition of toluene, media was removed and replaced with DMEM, 20 mmol/l HEPES, pH 7.2 to reduce background

phosphoERK1/2 (refs. (18,25)). After 1 h, toluene dissolved in media was added to the cell cultures. One dish was kept as a control, treated only with mouse IgG (MslgG). To form multimeric complexes, ASCS4 was cross-linked by mixing with goat anti-mouse IgG (1:2.5 g/g). The mixture was incubated for 1 h at 4 °C prior to addition to cells. One hour after addition of toluene, cross-linked ASCS4 (cASCs4) was added to the cell culture. Ten minutes after addition of the cASCs4 or MslgG, the cells were placed on ice, the media was removed, the cells were washed with ice-cold PBS, and cell lysates are prepared.

Preparation of Cell Lysates

All procedures were done at 4 °C. Cells were extracted in lysis buffer consisting of phosphatase inhibitor cocktail I (Sigma) in radioimmunoprecipitation assay buffer (Sigma) at 1:100. Cell extracts were incubated for 30 min and then centrifuged in a microfuge at maximum speed for 10 min. The cell lysate supernatants were transferred to clean microfuge tubes and stored at -4 °C.

Immunoblot for PhosphoERK1/2 and ERK1/2

For immunoblot analysis, cell lysate supernatants were analyzed for their protein concentration. 5 µg of each sample was measured out in clean microfuge tubes and boiled for 5 min in sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample buffer. The samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10% gel) and transferred to a polyvinylidene fluoride membrane. The membrane was blocked in Tris-buffered saline containing 2% BSA and 0.1% Tween-20. The membrane was incubated with antibodies to dually phosphorylated ERK1/2, washed, probed with horseradish peroxidase conjugated-goat anti-rabbit IgG, and reactive proteins were visualized with chemiluminescence. Blots were stripped and reprobed with anti-ERK1/2 antibodies to assess protein loading. The relative intensity of the bands was quantified using transmittance densitometry using Image J software (National Institutes of Health). The phosphoERK1/2 band densities were normalized for the amount of total ERK1/2 protein for all quantitative analyses. Relative densitometric units were determined by calculating the ratio of the normalized band densities to that of the MslgG control.

Statistical Analysis

The mean neurite length was determined for each condition from each cell preparation. Descriptive statistics determined the mean ± SEM neurite length from multiple cell preparations. Mean neurite length was compared between PLL and L1 or laminin alone by paired *t*-test to determine if L1 or laminin significantly increased neurite length. Mean neurite length of each ethanol (EtOH) or toluene treated culture was compared to L1 or laminin alone by paired *t*-test to determine if each concentration of toluene significantly reduced L1 or laminin-mediated neurite length. The relative amount of phosphoERK1/2 of cASCs4 treated cultures was compared to cultures treated with MslgG alone by paired *t*-test to determine if cASCs4 significantly increased phosphoERK1/2. The relative amount of phosphoERK1/2 of toluene and cASCs4 treated cultures was compared by paired *t*-test to cASCs4 treated cultures to determine if 0.1 mmol/l toluene significantly reduced L1 activation of ERK1/2. *P* < 0.05 was set as significant.

STATEMENT OF FINANCIAL SUPPORT

Funding for this project was provided by National Institutes of Health R01AA016398, Bethesda, MD (C.F.B.), Cobey Endowment (C.F.B.), the Munro Fund (C.F.B.), and the University of Maryland School of Medicine Student Research Training Program (K.M.R.W.).

Disclosure: The authors declare they have no actual or potential competing financial interests.

REFERENCES

- Sack TM, Steele DH. A survey of household products for volatile organic compounds. *Atmospheric Environment*. 1992;26A:1063-1070.
- Agency for Toxic Substances and Disease Registry. Toxicological profile for toluene. Atlanta, U.S. Public Health Service: U.S. Dept. of Health and Human Services 2000;1-357.
- Substance Abuse and Mental Health Services Administration. Results from the 2007 national survey on drug use and health: National findings 2007;1-241.
- Toutant C, Lippmann S. Fetal solvents syndrome. *Lancet* 1979;1:1356.
- Wilkins-Haug L. Teratogen update: toluene. *Teratology* 1997;55:145-51.
- Bowen SE, Balster RL. A direct comparison of inhalant effects on locomotor activity and schedule-controlled behavior in mice. *Exp Clin Psychopharmacol* 1998;6:235-47.
- Garlantézec R, Monfort C, Rouget F, Cordier S. Maternal occupational exposure to solvents and congenital malformations: a prospective study in the general population. *Occup Environ Med* 2009;66:456-63.
- Julvez J, Grandjean P. Neurodevelopmental toxicity risks due to occupational exposure to industrial chemicals during pregnancy. *Ind Health* 2009;47:459-68.
- Bowen SE. Two serious and challenging medical complications associated with volatile substance misuse: sudden sniffing death and fetal solvent syndrome. *Subst Use Misuse* 2011;46 Suppl 1:68-72.
- Bowen SE, Irtenkauf S, Hannigan JH, Stefanski AL. Alterations in rat fetal morphology following abuse patterns of toluene exposure. *Reprod Toxicol* 2009;27:161-9.
- Perrine SA, O'Leary-Moore SK, Galloway MP, Hannigan JH, Bowen SE. Binge toluene exposure alters glutamate, glutamine and GABA in the adolescent rat brain as measured by proton magnetic resonance spectroscopy. *Drug Alcohol Depend* 2011;115:101-6.
- Pearson MA, Hoyme HE, Seaver LH, Rimsza ME. Toluene embryopathy: delineation of the phenotype and comparison with fetal alcohol syndrome. *Pediatrics* 1994;93:211-5.
- Scheeres JJ, Chudley AE. Solvent abuse in pregnancy: a perinatal perspective. *J Obstet Gynaecol Can* 2002;24:22-6.
- Jones HE, Balster RL. Inhalant abuse in pregnancy. *Obstet Gynecol Clin North Am* 1998;25:153-67.
- Hersh JH, Podruch PE, Rogers G, Weisskopf B. Toluene embryopathy. *J Pediatr* 1985;106:922-7.
- Goodwin TM. Toluene abuse and renal tubular acidosis in pregnancy. *Obstet Gynecol* 1988;71:715-8.
- Arnold GL, Kirby RS, Langendoerfer S, Wilkins-Haug L. Toluene embryopathy: clinical delineation and developmental follow-up. *Pediatrics* 1994;93:216-20.
- Arai H, Yamada M, Miyake S, et al. [Two cases of toluene embryopathy with severe motor and intellectual disabilities syndrome]. *No To Hattatsu* 1997;29:361-6.
- Hannigan JH, Bowen SE. Reproductive toxicology and teratology of abused toluene. *Syst Biol Reprod Med* 2010;56:184-200.
- Hersh JH. Toluene embryopathy: two new cases. *J Med Genet* 1989;26:333-7.
- Ramanathan R, Wilkemeyer MF, Mittal B, Perides G, Charness ME. Alcohol inhibits cell-cell adhesion mediated by human L1. *J Cell Biol* 1996;133:381-90.
- Bearer CF. L1 cell adhesion molecule signal cascades: targets for ethanol developmental neurotoxicity. *Neurotoxicology* 2001;22:625-33.
- Jouet M, Rosenthal A, Armstrong G, et al. X-linked spastic paraplegia (SPG1), MASA syndrome and X-linked hydrocephalus result from mutations in the L1 gene. *Nat Genet* 1994;7:402-7.
- Schaefer AW, Kamiguchi H, Wong EV, Beach CM, Landreth G, Lemmon V. Activation of the MAPK signal cascade by the neural cell adhesion molecule L1 requires L1 internalization. *J Biol Chem* 1999;274:37965-73.
- Biran V, Verney C, Ferriero DM. Perinatal cerebellar injury in human and animal models. *Neurol Res Int* 2012;2012:858929.
- Bearer CF, Swick AR, O'Riordan MA, Cheng G. Ethanol inhibits L1-mediated neurite outgrowth in postnatal rat cerebellar granule cells. *J Biol Chem* 1999;274:13264-70.
- Watanabe H, Yamazaki M, Miyazaki H, et al. Phospholipase D2 functions as a downstream signaling molecule of MAP kinase pathway in L1-stimulated neurite outgrowth of cerebellar granule neurons. *J Neurochem* 2004;89:142-51.
- Nakai Y, Kamiguchi H. Migration of nerve growth cones requires detergent-resistant membranes in a spatially defined and substrate-dependent manner. *J Cell Biol* 2002;159:1097-108.
- Tang N, Farah B, He M, et al. Ethanol causes the redistribution of L1 cell adhesion molecule in lipid rafts. *J Neurochem* 2011;119:859-67.

30. Simons K, Gerl MJ. Revitalizing membrane rafts: new tools and insights. *Nat Rev Mol Cell Biol* 2010;11:688–99.
31. Littner Y, Tang N, He M, Bearer CF. L1 cell adhesion molecule signaling is inhibited by ethanol in vivo. *Alcohol Clin Exp Res* 2013;37:383–9.
32. Yeane NK, He M, Tang N, et al. Ethanol inhibits L1 cell adhesion molecule tyrosine phosphorylation and dephosphorylation and activation of pp60(src). *J Neurochem* 2009;110:779–90.
33. Tang N, He M, O’Riordan MA, et al. Ethanol inhibits L1 cell adhesion molecule activation of mitogen-activated protein kinases. *J Neurochem* 2006;96:1480–90.
34. Schmid RS, Pruitt WM, Maness PF. A MAP kinase-signaling pathway mediates neurite outgrowth on L1 and requires Src-dependent endocytosis. *J Neurosci* 2000;20:4177–88.
35. Lu S, Ouyang M, Seong J, Zhang J, Chien S, Wang Y. The spatiotemporal pattern of Src activation at lipid rafts revealed by diffusion-corrected FRET imaging. *PLoS Comput Biol* 2008;4:e1000127.
36. Joo S, Kang K, Nam Y. *In vitro* neurite guidance effects induced by polylysine pinstripe micropatterns with polylysine background. *J Biomed Mater Res A* 2015;103:2731–9.
37. Milstone AM, Bamford P, Aucott SW, Tang N, White KR, Bearer CF. Chlorhexidine inhibits L1 cell adhesion molecule-mediated neurite outgrowth *in vitro*. *Pediatr Res* 2014;75:8–13.
38. Hockberger PE, Tseng HY, Connor JA. Immunocytochemical and electrophysiological differentiation of rat cerebellar granule cells in explant cultures. *J Neurosci* 1987;7:1370–83.
39. Beattie CE, Siegel RE. Developmental cues modulate GABAA receptor subunit mRNA expression in cultured cerebellar granule neurons. *J Neurosci* 1993;13:1784–92.
40. Centers for Disease Control and Prevention. Fourth National Exposure Report, Updated Tables, February 2015. http://www.cdc.gov/biomonitoring/Toluene_BiomonitoringSummary.html. Accessed 15 November 2015.
41. Ashley DL, Bonin MA, Cardinali FL, McCraw JM, Wooten JV. Blood concentrations of volatile organic compounds in a nonoccupationally exposed US population and in groups with suspected exposure. *Clin Chem* 1994;40(7 Pt 2):1401–4.
42. Buckley TJ, Liddle J, Ashley DL, et al. Environmental and biomarker measurements in nine homes in the lower Rio Grande Valley: Multimedia results for pesticides, metals, PAHs, and VOCs. *Environ Int* 1997;23:705–732.
43. Carrer P, Maroni M, Alcini D, et al. Assessment through environmental and biological measurements of total daily exposure to volatile organic compounds of office workers in Milan, Italy. *Indoor Air* 2000;10:258–68.
44. Perbellini L, Pasini F, Romani S, et al. Analysis of benzene, toluene, ethylbenzene and m-xylene in biological samples from the general population. *J Chromatogr B* 2002;778:199–210.
45. Brugnone F, Gobbi M, Ayyad K, Giuliani C, Cerpelloni M, Perbellini L. Blood toluene as a biological index of environmental toluene exposure in the “normal” population and in occupationally exposed workers immediately after exposure and 16 hours later. *Int Arch Occup Environ Health* 1995;66:421–5.
46. Romieu I, Ramirez M, Meneses F, et al. Environmental exposure to volatile organic compounds among workers in Mexico City as assessed by personal monitors and blood concentrations. *Environ Health Perspect* 1999;107:511–5.
47. Neubert D, Bochert G, Gericke C, Hanke B, Beckmann G; Toluene Field Study Group. Multicenter field trial on possible health effects of toluene. I. Toluene body burdens in workers of the rotogravure industry. *Toxicology* 2001;168:139–57.
48. Hammer KD. Metabolite ratio of toluene-exposed rotogravure printing plant workers reflects individual mutagenic risk by sister chromatid exchanges. *Mutat Res* 2002;519:171–7.
49. Garriott JC, Foerster E, Juarez L, de la Garza F, Mendiola I, Curoe J. Measurement of toluene in blood and breath in cases of solvent abuse. *Clin Toxicol* 1981;18:471–9.
50. Thiesen FV, Noto AR, Barros HM. Laboratory diagnosis of toluene-based inhalants abuse. *Clin Toxicol (Phila)* 2007;45:557–62.